Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers

PURPOSE: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such treatment. PATIENTS AND METHODS: In the NeoAva phase II clinical trial, patients (N = 132) with large (≥ 2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Haugen, Mads H., Lingjærde, Ole Christian, Hedenfalk, Ingrid, Garred, Øystein, Borgen, Elin, Loman, Niklas, Hatschek, Thomas, Børresen-Dale, Anne-Lise, Naume, Bjørn, Mills, Gordon B., Mælandsmo, Gunhild M., Engebraaten, Olav
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2021
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8140811/
https://ncbi.nlm.nih.gov/pubmed/34036235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00086
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados